Uncategorized

BridgeBio touts kidney benefits for Attruby, differentiating from amyloidosis competitors

Published

on

BridgeBio’s Attruby preserves kidney function in patients with transthyretin amyloidosis cardiomyopathy, an effect that is “distinct” from other drugs in this space, according to Jefferies.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version